MIM
TNYA icon

MetLife Investment Management’s Tenaya Therapeutics TNYA Stock Holding History

MetLife Investment Management’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-31,642
Closed -$98.1K – 2894
2024
Q2 		$98.1K Buy
31,642
+5,751
+22% +$23.8K ﹤0.01% 2614
2024
Q1 		$135K Buy
+25,891
New +$124K ﹤0.01% 2393
2023
Q4 		– Sell
-25,148
Closed -$64.1K – 2862
2023
Q3 		$64.1K Hold
25,148
– – ﹤0.01% 2790
2023
Q2 		$148K Buy
+25,148
New +$146K ﹤0.01% 2449
2022
Q2 		– Sell
-18,722
Closed -$221K – 2906
2022
Q1 		$221K Buy
18,722
+12,865
+220% +$156K ﹤0.01% 2297
2021
Q4 		$111K Hold
5,857
– – ﹤0.01% 2373
2021
Q3 		$121K Buy
+5,857
New +$126K ﹤0.01% 2354

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

MetLife Investment Management's TNYA Position: Q3 2024 in Review

MetLife Investment Management sold out of Tenaya Therapeutics (TNYA) in Q3 2024, closing a stake of 31,642 shares — an estimated $98.1K sold.

MetLife Investment Management first reported a position in TNYA in Q3 2021 and held it in 7 quarters. The position peaked at $221K in Q1 2022. 95 funds tracked by Wall St. Rank hold TNYA as of Q3 2024.

  • MetLife Investment Management reported no remaining Tenaya Therapeutics position as of Q3 2024 after selling out during the quarter.
  • MetLife Investment Management sold 31,642 Tenaya Therapeutics shares in Q3 2024, an estimated $98.1K.
  • MetLife Investment Management first reported a position in Tenaya Therapeutics in Q3 2021 and held it in 7 quarters.
  • MetLife Investment Management's Tenaya Therapeutics position peaked at $221K in Q1 2022.
  • 95 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q3 2024.

Based on MetLife Investment Management's 13F filing for Q3 2024, filed 13 Nov 2024.